Jadvar H, Calais J, Fanti S, Feng F, Greene KL, Gulley JL, et al. Appropriate use criteria for prostate-specific membrane antigen PET imaging. J Nucl Med. 2022;63:59–68.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243–62.

Article  CAS  PubMed  Google Scholar 

Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically localized prostate cancer: AUA/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J Urol. 2022;208:10–18.

Article  PubMed  Google Scholar 

Yaxley JW, Raveenthiran S, Nouhaud FX, Samaratunga H, Yaxley WJ, Coughlin G, et al. Risk of metastatic disease on 68gallium-prostate-specific membrane antigen positron emission tomography/computed tomography scan for primary staging of 1253 men at the diagnosis of prostate cancer. BJU Int. 2019;124:401–7.

Article  CAS  PubMed  Google Scholar 

Rogasch JM, Cash H, Zschaeck S, Elezkurtaj S, Brenner W, Hamm B, et al. Ga-68-PSMA PET/CT in treatment-naïve patients with prostate cancer: which clinical parameters and risk stratification systems best predict PSMA-positive metastases? Prostate. 2018;78:1103–10.

Article  CAS  Google Scholar 

Hagens MJ, Luining WI, Jager A, Donswijk ML, Cheung Z, Wondergem M, et al. The diagnostic value of PSMA PET/CT in men with newly diagnosed unfavorable intermediate-risk prostate cancer. J Nucl Med. 2023;64:1238–43.

Article  CAS  PubMed  Google Scholar 

Haller S. The concept of “number needed to image”. AJNR Am J Neuroradiol. 2017;38:E79–80.

Article  CAS  PubMed  PubMed Central  Google Scholar 

de Feria Cardet RE, Hofman MS, Segard T, Yim J, Williams S, Francis RJ, et al. Is Prostate-specific membrane antigen positron emission tomography/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA trial. Eur Urol. 2021;79:413–8.

Article  PubMed  Google Scholar 

Tokuda Y, Carlino LJ, Gopalan A, Tickoo SK, Kaag MG, Guillonneau B, et al. Prostate cancer topography and patterns of lymph node metastasis. Am J Surg Pathol. 2010;34:1862–7.

Article  PubMed  PubMed Central  Google Scholar 

Luining WI, Boevé LMS, Hagens MJ, Meijer D, de Weijer T, Ettema RH, et al. A comparison of globally applied prognostic risk groups and the prevalence of metastatic disease on prostate-specific membrane antigen positron emission tomography in patients with newly diagnosed prostate cancer. Eur Urol Oncol. 2024;S2588-9311(24)00097-X.

Hagens MJ, Oprea-Lager DE, Vis AN, Wondergem M, Donswijk ML, Meijer D, et al. Reproducibility of PSMA PET/CT imaging for primary staging of treatment-naïve prostate cancer patients depends on the applied radiotracer: a retrospective study. J Nucl Med. 2022;63:1531–6.

Article  CAS  PubMed  Google Scholar